Minnelide

DRUG6 trials

Sponsors

Minneamrita Therapeutics LLC, Justin Watts, H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI)

Conditions

Acute Myeloid LeukemiaAdenosquamous Carcinoma of the PancreasGastric CancerMetastatic Adenocarcinoma of the PancreasPancreatic Cancer

Phase 1

Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

WithdrawnNCT03347994

Justin WattsAcute Myeloid Leukemia

Start: 2018-04-30End: 2022-04-30Updated: 2018-03-06

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

TerminatedNCT03760523

H. Lee Moffitt Cancer Center and Research InstituteAcute Myeloid Leukemia

Start: 2019-04-18End: 2023-10-09Updated: 2026-01-07

Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Minneamrita Therapeutics LLCMetastatic Adenocarcinoma of the Pancreas

Start: 2022-11-01End: 2024-12-31Target: 36Updated: 2022-12-09

Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer

Minneamrita Therapeutics LLCGastric Cancer

Start: 2020-11-02End: 2024-11-30Target: 36Updated: 2023-10-18

Phase 2

A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer

CompletedNCT03117920

Minneamrita Therapeutics LLCPancreatic Cancer

Start: 2017-04-10End: 2019-07-01Updated: 2023-10-18

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

CompletedNCT04896073

National Cancer Institute (NCI)Adenosquamous Carcinoma of the Pancreas

Start: 2022-03-07End: 2025-03-30Updated: 2026-08-14

Related Papers

The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial.

2024-06-1010 citations

A phase 1 study to evaluate the safety and preliminary efficacy of minnelide given alone or in combination with paclitaxel in advanced gastric cancer.

Journal of Clinical Oncology2024-06-01

A phase 1b, open-label, safety, pharmacokinetic, and pharmacodynamic study of an anti–super-enhancer triptolide analogue with <i>nab</i>-paclitaxel plus gemcitabine in patients with metastatic adenocarcinoma of the pancreas.

Journal of Clinical Oncology2023-01-24

Abstract PO-054: A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP)

Cancer Research2021-11-151 citations

Abstract CT165: Phase II open label trial of minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer

Cancer Research2019-07-016 citations

Abstract CT165: Phase II open label trial of minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer

Clinical Trials2019-07-012 citations